orforglipron – Medxy AI

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY 09/27/2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies.

Clinical Updates Wellness & Lifestyle

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

By MedXY 09/17/2025

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Clinical Updates Wellness & Lifestyle

Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena

By MedXY 08/17/2025

Eli Lilly's oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying, promising diverse mechanisms and potential market shifts.